Ketotifen
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
|
|
| Clinical data | |
| Trade names | Zaditor[1] |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a604033 |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Oral (tablets), ophthalmic solution |
| Pharmacokinetic data | |
| Bioavailability | 60% |
| Protein binding | 75% |
| Metabolism | Hepatic |
| Biological half-life | 12 hours |
| Identifiers | |
| CAS Number | 34580-14-8  |
| ATC code | R06AX17 S01GX08 |
| PubChem | CID 3827 |
| IUPHAR/BPS | 7206 |
| DrugBank | DB00920 |
| ChemSpider | 3695 |
| UNII | HBD503WORO |
| KEGG | D01332 |
| ChEMBL | CHEMBL534 |
| Chemical data | |
| Formula | C19H19NOS |
| Molar mass | 309.426 g/mol |
|
|
|
|
| (verify) |
Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis,[2] or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
Uses[edit]
Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[3] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.
The drug may also help relieve the symptoms of irritable bowel syndrome.[4]
Side effects[edit]
 |
This section does not cite any sources. (June 2014) |
Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.
Brands[edit]
Ketotifen is marketed under many brand names worldwide.[5]
See also[edit]
References[edit]
- ^ http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details
- ^ a b Zaditor prescribing information Novartis
- ^ Grahnén A; Lönnebo A; Beck O; Eckernäs SA; Dahlström B; Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharm Drug Dispos 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111.
- ^ Klooker, TK; Braak, B; Koopman, KE; Welting, O; Wouters, MM; Van Der Heide, S; Schemann, M; Bischoff, SC; et al. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
- ^ drugs.com International availability of ketofin Page accessed April 21, 2015
External links[edit]
|
|
